• Users Online: 621
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
CASE REPORT
Year : 2019  |  Volume : 31  |  Issue : 4  |  Page : 981-982

Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus


Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt

Correspondence Address:
BSc Ahmed Shaker
Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, 12613
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejim.ejim_84_18

Rights and Permissions

Targeting B-cell in systemic lupus erythematosus (SLE) seems to be a promising approach. Although rituximab failed to show efficacy in refractory SLE in clinical trial setting, real-world experience still shows some efficacy in certain situations. A 20-year-old woman was diagnosed with SLE with coexistent myositis. The patient’s muscular condition did not improve on corticosteroids, addition of rituximab could achieve complete response. Introducing rituximab early for the nonrenal manifestations of SLE merits further investigation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed107    
    Printed4    
    Emailed0    
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal